정밀 정신의학 시장 보고서 : 제품 유형, 샘플, 바이오마커 유형, 기술, 용도, 최종사용자, 지역별(2025-2033년)

The global precision psychiatry market size reached USD 1,224 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 4,270.3 Million by 2033, exhibiting a growth rate (CAGR) of 14.9% during 2025-2033. The rising prevalence of mental health disorders among the masses, the growing need for personalized treatment plans and interventions and the advent of genetic testing, and data analytics represent some of the key factors driving the market.

Precision psychiatry refers to an innovative medical approach that is widely adopted for mental health care. It leverages numerous advanced technologies and personalized medicine to provide more targeted and effective treatments for individuals suffering from psychiatric disorders. It recognizes that mental illnesses, such as depression, anxiety, bipolar disorder, and schizophrenia, are complex and multifaceted conditions influenced by a combination of genetic, environmental, and lifestyle factors. It aims to tailor multiple interventions based on an individual's unique characteristics, including their genetic makeup, neurobiological markers, and personal circumstances. It allows clinicians to gain deeper insights into the underlying mechanisms of psychiatric disorders and develop personalized treatment plans accordingly. Besides this, it also identifies specific genetic variations that may contribute to the susceptibility to certain mental health conditions or influence the response to particular medications. This information allows for the selection of more appropriate and targeted treatment options, increasing the likelihood of positive outcomes while minimizing the potential for adverse effects.

Precision Psychiatry Market Trends:

The global market is majorly driven by the rising prevalence of mental health disorders among the masses. Coupled with the growing need for personalized treatment plans and interventions, there has been a considerable increase in the adoption of precision psychiatry among individuals. Since precision psychiatry aligns with the broader trend toward personalized medicine across various medical fields. It recognizes that each individual is unique and requires tailored treatments based on their genetic, neurobiological, and environmental factors. This personalized approach resonates with patients, as it offers the prospect of more effective treatments and improved outcomes, which is gaining widespread prominence among the masses. Moreover, continual technological advancements, such as the advent of genetic testing, neuroimaging, and data analytics have significantly contributed to the development and implementation of precision psychiatry, further impacting the market favorably. Apart from this, the growing interest in precision psychiatry is accompanied by rising research activities and funding support. Academic institutions, research organizations, and pharmaceutical companies are investing in research to better understand the biological mechanisms of psychiatric disorders and develop targeted treatments, hence providing an impetus to the market. Other factors, including rapid urbanization, growing awareness among individuals and continual developments in the healthcare infrastructure, are also positively influencing the market.

Key Market Segmentation:

Product Type Insights:

• Products
• Services

Sample Insights:

• Blood-Based
• Non-Blood-Based
• Saliva
• Urine
• Cerebral Spinal Fluid (CSF)
• Others

Biomarker Type Insights:

• Genetic Biomarker
• Protein Biomarker

Technology Insights:

• Sequencing
• Next-Generation Sequencing (NGS)
• Sanger Sequencing
• Polymerase Chain Reaction (PCR)
• Real-Time Polymerase Chain Reaction (RT-PCR)
• Digital Polymerase Chain Reaction (dPCR)
• Microarray
• Immunoassay
• Liquid Chromatography-Mass Spectrometry (LC-MS)
• Others

Application Insights:

• Alzheimer's Disease
• Parkinson's Disease
• Autism
• Depression
• Bipolar Disease
• Others

End User Insights:

• Hospitals and Diagnostic Laboratories
• Academic and Research Institutions
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for precision psychiatry. Some of the factors driving the North America precision psychiatry market included the growing awareness among the masses, the emerging healthcare industry, the shifting lifestyle preferences of the masses, etc.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global precision psychiatry market. Detailed profiles of all major companies have been provided. Some of the companies covered include Altimate Healthcare, Alto Nanoscience, ATAI Life Sciences N.V., Fulgent Genetics Inc, Invitae Corporation, Myriad Genetics Inc., Precision Psychiatric Services Inc., Tempus Labs Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global precision psychiatry market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global precision psychiatry market?
• What is the impact of each driver, restraint, and opportunity on the global precision psychiatry market?
• What are the key regional markets?
• Which countries represent the most attractive precision psychiatry market?
• What is the breakup of the market based on the product type?
• Which is the most attractive product type in the precision psychiatry market?
• What is the breakup of the market based on the sample?
• Which is the most attractive sample in the precision psychiatry market?
• What is the breakup of the market based on the biomarker type?
• Which is the most attractive biomarker type in the precision psychiatry market?
• What is the breakup of the market based on technology?
• Which is the most attractive technology in the precision psychiatry market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the precision psychiatry market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the precision psychiatry market?
• What is the competitive structure of the global precision psychiatry market?
• Who are the key players/companies in the global precision psychiatry market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Precision Psychiatry Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Products
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Services
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Sample

• 7.1 Blood-Based
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Non-Blood-Based
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Saliva
    • 7.2.2.2 Urine
    • 7.2.2.3 Cerebral Spinal Fluid (CSF)
    • 7.2.2.4 Others
  • 7.2.3 Market Forecast

8 Market Breakup by Biomarker Type

• 8.1 Genetic Biomarker
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Protein Biomarker
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Technology

• 9.1 Sequencing
  • 9.1.1 Market Trends
  • 9.2.2 Key Segments
    • 9.2.2.1 Next-Generation Sequencing (NGS)
    • 9.2.2.2 Sanger Sequencing
  • 9.1.3 Market Forecast
• 9.2 Polymerase Chain Reaction (PCR)
  • 9.2.1 Market Trends
  • 9.2.2 Key Segments
    • 9.2.2.1 Real-Time Polymerase Chain Reaction (RT-PCR)
    • 9.2.2.2 Digital Polymerase Chain Reaction (dPCR)
  • 9.2.3 Market Forecast
• 9.3 Microarray
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Immunoassay
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Liquid Chromatography-Mass Spectrometry (LC-MS)
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast
• 9.6 Others
  • 9.6.1 Market Trends
  • 9.6.2 Market Forecast

10 Market Breakup by Application

• 10.1 Alzheimer's Disease
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Parkinson's Disease
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Autism
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Depression
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Bipolar Disease
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast
• 10.6 Others
  • 10.6.1 Market Trends
  • 10.6.2 Market Forecast

11 Market Breakup by End User

• 11.1 Hospitals and Diagnostic Laboratories
  • 11.1.1 Market Trends
  • 11.1.2 Market Forecast
• 11.2 Academic and Research Institutions
  • 11.2.1 Market Trends
  • 11.2.2 Market Forecast
• 11.3 Others
  • 11.3.1 Market Trends
  • 11.3.2 Market Forecast

12 Market Breakup by Region

• 12.1 North America
  • 12.1.1 United States
    • 12.1.1.1 Market Trends
    • 12.1.1.2 Market Forecast
  • 12.1.2 Canada
    • 12.1.2.1 Market Trends
    • 12.1.2.2 Market Forecast
• 12.2 Asia-Pacific
  • 12.2.1 China
    • 12.2.1.1 Market Trends
    • 12.2.1.2 Market Forecast
  • 12.2.2 Japan
    • 12.2.2.1 Market Trends
    • 12.2.2.2 Market Forecast
  • 12.2.3 India
    • 12.2.3.1 Market Trends
    • 12.2.3.2 Market Forecast
  • 12.2.4 South Korea
    • 12.2.4.1 Market Trends
    • 12.2.4.2 Market Forecast
  • 12.2.5 Australia
    • 12.2.5.1 Market Trends
    • 12.2.5.2 Market Forecast
  • 12.2.6 Indonesia
    • 12.2.6.1 Market Trends
    • 12.2.6.2 Market Forecast
  • 12.2.7 Others
    • 12.2.7.1 Market Trends
    • 12.2.7.2 Market Forecast
• 12.3 Europe
  • 12.3.1 Germany
    • 12.3.1.1 Market Trends
    • 12.3.1.2 Market Forecast
  • 12.3.2 France
    • 12.3.2.1 Market Trends
    • 12.3.2.2 Market Forecast
  • 12.3.3 United Kingdom
    • 12.3.3.1 Market Trends
    • 12.3.3.2 Market Forecast
  • 12.3.4 Italy
    • 12.3.4.1 Market Trends
    • 12.3.4.2 Market Forecast
  • 12.3.5 Spain
    • 12.3.5.1 Market Trends
    • 12.3.5.2 Market Forecast
  • 12.3.6 Russia
    • 12.3.6.1 Market Trends
    • 12.3.6.2 Market Forecast
  • 12.3.7 Others
    • 12.3.7.1 Market Trends
    • 12.3.7.2 Market Forecast
• 12.4 Latin America
  • 12.4.1 Brazil
    • 12.4.1.1 Market Trends
    • 12.4.1.2 Market Forecast
  • 12.4.2 Mexico
    • 12.4.2.1 Market Trends
    • 12.4.2.2 Market Forecast
  • 12.4.3 Others
    • 12.4.3.1 Market Trends
    • 12.4.3.2 Market Forecast
• 12.5 Middle East and Africa
  • 12.5.1 Market Trends
  • 12.5.2 Market Breakup by Country
  • 12.5.3 Market Forecast

13 Drivers, Restraints, and Opportunities

• 13.1 Overview
• 13.2 Drivers
• 13.3 Restraints
• 13.4 Opportunities

14 Value Chain Analysis

15 Porters Five Forces Analysis

• 15.1 Overview
• 15.2 Bargaining Power of Buyers
• 15.3 Bargaining Power of Suppliers
• 15.4 Degree of Competition
• 15.5 Threat of New Entrants
• 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

• 17.1 Market Structure
• 17.2 Key Players
• 17.3 Profiles of Key Players
  • 17.3.1 Altimate Healthcare
    • 17.3.1.1 Company Overview
    • 17.3.1.2 Product Portfolio
  • 17.3.2 Alto Nanoscience
    • 17.3.2.1 Company Overview
    • 17.3.2.2 Product Portfolio
  • 17.3.3 ATAI Life Sciences N.V.
    • 17.3.3.1 Company Overview
    • 17.3.3.2 Product Portfolio
  • 17.3.4 Fulgent Genetics Inc.
    • 17.3.4.1 Company Overview
    • 17.3.4.2 Product Portfolio
  • 17.3.5 Invitae Corporation
    • 17.3.5.1 Company Overview
    • 17.3.5.2 Product Portfolio
  • 17.3.6 Myriad Genetics Inc.
    • 17.3.6.1 Company Overview
    • 17.3.6.2 Product Portfolio
  • 17.3.7 Precision Psychiatric Services Inc.
    • 17.3.7.1 Company Overview
    • 17.3.7.2 Product Portfolio
  • 17.3.8 Tempus Labs Inc.
    • 17.3.8.1 Company Overview
    • 17.3.8.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.